Research Topics
| Maria Victoria MateosSummaryAffiliation: Universidad de Salamanca Country: Spain Publications
| Collaborators
|
Detail Information
Publications
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse eventsMaria Victoria Mateos
Hematology Department, University Hospital of Salamanca, Salamanca, Spain
Leuk Res 36:S35-43. 2012..AEs are generally transient, occurring early in the course of treatment, providing evidence for the feasibility of continuous therapy...
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialMaria Victoria Mateos
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer Universidad de Salamanca Consejo Superior de Investigaciones Científicas, Salamanca, Spain
Blood 120:2581-8. 2012..In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235...- Role of bortezomib for the treatment of previously untreated multiple myelomaMaria Victoria Mateos
Hematology Department, University Hospital of Salamanca, Salamanca, Spain
Expert Rev Hematol 1:17-28. 2008..These results allow bortezomib-based combination therapy to be established as key options for patients with previously untreated multiple myeloma... - Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaria Victoria Mateos
University Hospital of Salamanca, Salamanca, Spain
Blood 118:4547-53. 2011..02). The present schema does not overcome the negative prognosis of high-risk CAs and nonhyperdiploidy. This trial was registered with www.ClinicalTrials.gov as NCT00443235... - Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelomMaria Victoria Mateos
University Hospital of Salamanca, Salamanca, Spain
Lancet Oncol 11:934-41. 2010..We investigated a novel and less intensive bortezomib-based regimen to maintain efficacy and to reduce toxic effects... - Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaria Victoria Mateos
Departamento de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
Clin Cancer Res 16:3260-9. 2010..This trial evaluated the antitumor activity and safety of the marine-derived cyclodepsipeptide plitidepsin in patients with relapsed/refractory multiple myeloma... - Management of treatment-related adverse events in patients with multiple myelomaMaria Victoria Mateos
Haematology Department, University Hospital of Salamanca, Salamanca, Spain
Cancer Treat Rev 36:S24-32. 2010..We further review the management of these adverse events with a view to delivering optimal therapeutic outcomes in patients with newly diagnosed and relapsed and/or refractory multiple myeloma... - Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesus F San Miguel
Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
J Clin Oncol 31:448-55. 2013.... - Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trialsBruno Paiva
Hospital Universitario de Salamanca, Spain
Am J Pathol 181:1870-8. 2012..NH-MM and a high proliferation index assessed by multiparameter flow cytometry remain as independent prognostic factors in MM, but the latter may be overcome by incorporating novel agents in the HDT/ASCT setting... - Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
J Clin Oncol 29:1627-33. 2011..To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents... - High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva
Hospital Universitario de Salamanca, Spain
Blood 119:687-91. 2012..0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated... - Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialMaria Victoria Mateos
Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
J Clin Oncol 28:2259-66. 2010.... - Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progressionMaria Victoria Mateos
Hospital Universitario de Salamanca, Salamanca, Spain
Haematologica 93:560-5. 2008..Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome... - The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
Blood 114:4369-72. 2009..This trial was registered at www.clinicaltrials.gov as NCT00560053... - Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experienceAdrian Alegre
Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain
Leuk Lymphoma 53:1714-21. 2012..gov: NCT00420849)... - The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cellsLucía López-Corral
Servicio de Hematologia, Hospital Universitario, Universidad de Salamanca, Salamanca, Spain
Clin Cancer Res 17:1692-700. 2011..Our aim was to investigate in depth the level of clonal heterogeneity of recurrent genetic abnormalities in these conditions... 
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patientsBruno Paiva
Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
Haematologica 94:1599-602. 2009..clinicaltrials.gov identifier: NCT00560053)...- Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survivalJuan Jose Lahuerta
Hospital Universitario de Salamanca, Salamanca, Spain
J Clin Oncol 26:5775-82. 2008..We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM... - Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?Maria Victoria Mateos
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
Br J Haematol 140:324-6. 2008..Consequently, G-CSF could be effective in preventing further neutropenia-related complications without compromising treatment efficacy in MM patients with lenalidomide-induced neutropenia... - The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosisBruno Paiva
Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, Salamanca, Spain
Blood 117:3613-6. 2011..01). MFC immunophenotyping could be clinically useful for the demonstration of PC clonality in AL and for the prognostication of patients with AL... - Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio
University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
Expert Opin Investig Drugs 21:1075-87. 2012.... - Genomic analysis of high-risk smoldering multiple myelomaLucía López-Corral
Servicio de Hematología del Hospital Universitario de Salamanca y Centro de Investigación del Cáncer IBMCC USAl CIC, Universidad de Salamanca, Salamanca, Spain
Haematologica 97:1439-43. 2012..These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235)... - Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesus F San Miguel
Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
N Engl J Med 359:906-17. 2008..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy... - Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometryRoberto J Pessoa de Magalhães
Hospital Universitario de Salamanca, Salamanca, Spain
Haematologica 98:79-86. 2013.... - New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findingsEnrique M Ocio
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
Lancet Oncol 9:1157-65. 2008..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents... - New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cellsErnesto Pérez Persona
Department of Hematology, University Hospital, Salamanca, Spain
Blood 110:2586-92. 2007..001). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients... - [Multiple myeloma]Ramon Garcia-Sanz
Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Salamanca, Espana
Med Clin (Barc) 129:104-15. 2007.... - Medium-term results of percutaneous vertebroplasty in multiple myelomaLuis Ramos
Department of Orthopaedic Surgery, University Hospital of Salamanca, Salamanca, Spain
Eur J Haematol 77:7-13. 2006..PVP is associated with early clinical improvement of pain and function and can be maintained after a long follow-up without major procedure-related complications...